If you have been reading about peptide mapping and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Entry clones must be made using the supplied "Donor" vectors containing a Gateway cassette flanked by attP sites. The Gateway cassette contains a bacterial suicide gene (e.g. ccdB) that will allow for survival and selection of successfully recombined entry clones. A pair of attB sites are added to flank the DNA fragment of interest, and this will allow recombination with the attP sites when the BP clonase mix is added. Entry clones are produced, and the fragment of interest is flanked by attL sites. The destination vector also comes with a Gateway cassette, but is instead flanked by a pair of attR sites. Mixing this destination plasmid with the entry clones and the LR clonase mix will allow for recombination to occur between the attR and attL sites. A destination clone is produced, with the fragment of interest successfully inserted. The lethal gene is inserted into the original vector, and bacteria transformed with this plasmid will die. The desired vector can thus be easily selected. The earliest iterations of the Gateway cloning method only allowed for only one entry clone to be used for each destination clone produced. However, further research revealed that four more orthogonal att sequences could be generated, allowing for the assembly of up to four different DNA fragments, and this process is now known as the Multisite Gateway technology. Besides Gateway cloning, non-commercial methods using other integrases have also been developed.
During torpor, bats drop their body temperature to 6–30 °C (43–86 °F), while their energy usage diminishes by 50 to 99%. Tropical bats may use it to reduce the chance of being caught by a predator during foraging. Megabats were generally believed to be homoeothermic, but three species of small megabats, with a mass of about 50 grams (1+3⁄4 ounces), have been known to use torpor: the common blossom bat (Syconycteris australis), the long-tongued nectar bat (Macroglossus minimus), and the eastern tube-nosed bat (Nyctimene robinsoni). Torpid states last longer in the summer for megabats than in the winter. During hibernation, bats enter a torpid state and decrease their body temperature for 99.6% of their hibernation period; even during periods of arousal, when their body temperature returns to normal, they sometimes enter a shallow torpid state, known as "heterothermic arousal". Some bats become dormant during higher temperatures to keep cool in the summer months (aestivation). Heterothermic bats during long migrations may fly at night and go into a torpid state roosting in the daytime. Unlike migratory birds, which fly during the day and feed during the night, nocturnal bats have a conflict between travelling and eating. The energy saved reduces their food requirements and also decreases the duration of migration, which may prevent them from spending too much time in unfamiliar places and decrease predation. In some species, pregnant individuals use a more moderate state of torpor to maintain foetal development, while still saving energy.
Vaginal discharge may indicate a vaginal infection by color and odor, or the resulting symptoms of discharge, such as irritation or burning. Abnormal vaginal discharge may be caused by STIs, diabetes, douches, fragranced soaps, bubble baths, birth control pills, yeast infection (commonly as a result of antibiotic use) or another form of vaginitis. While vaginitis is an inflammation of the vagina, and is attributed to infection, hormonal issues, or irritants, vaginismus is an involuntary tightening of the vagina muscles during vaginal penetration that is caused by a conditioned reflex or disease. Vaginal discharge due to yeast infection is usually thick, creamy in color and odorless, while discharge due to bacterial vaginosis is gray-white in color, and discharge due to trichomoniasis is usually a gray color, thin in consistency, and has a fishy odor. Discharge in 25% of the trichomoniasis cases is yellow-green. HIV/AIDS, human papillomavirus (HPV), genital herpes and trichomoniasis are some STIs that may affect the vagina, and health sources recommend safe sex (or barrier method) practices to prevent the transmission of these and other STIs. Safe sex commonly involves the use of condoms, and sometimes female condoms (which give women more control). Both types can help avert pregnancy by preventing semen from coming in contact with the vagina.
Sources: en.wikipedia.org
=== Israel === Israel declared a nationwide state of emergency, saying that the strikes on Iran were the largest that it had ever launched. Israeli schools and workspaces were closed and public gatherings were canceled. In the 40 days from the start of the war through the 8 April ceasefire, there were a total of 650 missile attacks from Iran to Israel, the majority of which carried cluster munitions. About 16 of the missiles that made it past Israeli missile defenses carried conventional warheads, while 50 had cluster munitions. The attacks killed a total of 24 people, all of them civilians, and resulted in more than 7,000 injuries. Of the 24 civilians killed, 14 were struck by conventional explosive warheads and 10 by cluster submunitions. Two of the deaths were inside a sheltered space, with the other fatalities being people in unprotected areas.
from the Miocene strata of the Santalla Formation (Spain), representing the first large vertebrate from the El Bierzo Basin reported to date. A study on deciduous teeth and juvenile skulls of members of the genus Chilotherium, providing evidence of utility of dental characters for species discrimination, is published by Kampouridis et al. (2026). Pandolfi, Codrea & Solomon (2026) describe fossil material of a member of the genus Acerorhinus from the Miocene strata from the Crețești 1 site (Romania), with greatest similarity to A. simplex, and refine the species content of the genus Acerorhinus. Titov et al. (2026) describe fossil material of Elasmotherium chaprovicum from the Pleistocene strata from the Taurida Cave (Crimea), including the first upper milk teeth of a member of the genus Elasmotherium reported to date. Ponomarev et al. (2026) report the discovery of fossil material of Stephanorhinus kirchbergensis in the Pleistocene strata from the Komi Republic (Russia), representing the northernmost record of the species in Europe reported to date. Uzunidis & Pandolfi (2026) report evidence of different dynamics of evolution of body mass of the narrow-nosed rhinoceros from Northern Europe and from the Mediterranean, as well as evidence of consistent mixed-feeding strategy in the studied species, with seasonal specialization toward either browsing or grazing in populations near the end of the temporal range of the species.
== Career == Clausen was elected as a member of the Legislative Assembly for the Stanley constituency in the 2005 election. She was elected as a member of the Legislative Council, which was reconstituted into the Legislative Assembly with the implementation of the 2009 Constitution. Clausen was elected to the Legislative Council at the 2005 general election, but lost her seat four years later in the 2009 general election. In October 2019, Clausen became the Director of Natural Resources for the Falkland Islands Government. This role had a wide-ranging remit, from supporting the economic growth of the Islands to helping ensure the sustainability of fisheries, farming and natural environment. In 2024, it was announced that she had been appointed to succeed Andy Keeling as Chief Executive of the Falkland Islands Government. She is the first resident of the Falkland Islands and first woman to hold the position.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.